Please login to the form below

Not currently logged in
Email:
Password:

metastatic colorectal cancer

This page shows the latest metastatic colorectal cancer news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices

Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices

or mismatch repair deficient (dMMR) metastatic colorectal cancer. ... About 4% to 5% of metastatic colorectal cancer patients have those mutations, and make them less likely to benefit from conventional chemotherapy.

Latest news

  • Another IO knockback as Tecentriq combo fails phase III trial Another IO knockback as Tecentriq combo fails phase III trial

    The IMblaze370 trial of PD-L1 inhibitor Tecentriq (atezolizumab) and MEK inhibitor Cotellic (cobimetinib) as a third-line treatment option in people with difficult-to-treat, locally advanced or metastatic colorectal ... In particular, we have a number of

  • BMS closes in on colorectal cancer indication for Opdivo BMS closes in on colorectal cancer indication for Opdivo

    BMS is seeking approval for Opdivo (nivolumab) in patients with two specific biomarkers metastatic colorectal cancer who have already been treated first-line with chemotherapy. ... We look forward to working with the FDA towards the goal of providing a

  • AZ withdraws EU filing for ovarian cancer drug cediranib AZ withdraws EU filing for ovarian cancer drug cediranib

    AZ withdraws EU filing for ovarian cancer drug cediranib. Maintains cediranib’ s value as a combination therapy despite EMA information request. ... as well as a late-stage trial in metastatic colorectal cancer in which it was compared to Roche's

  • Opdivo backed for two new uses by CHMP Opdivo backed for two new uses by CHMP

    Opdivo has been given a positive opinion in previously-treated renal cell carcinoma (RCC) and previously-treated metastatic non-squamous non-small cell lung cancer (NSCLC), adding to its existing approvals ... Meanwhile, Servier got the CHMP's backing

  • Incyte abandons solid tumour programme for Jakafi Incyte abandons solid tumour programme for Jakafi

    advanced or metastatic pancreatic cancer. ... In January, Incyte announced that a phase II trial of the drug given in tandem with Bayer's Stivarga (regorafenib) as a treatment for patients with relapsed or refractory metastatic colorectal

More from news
Approximately 2 fully matching, plus 70 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    CAP7.1 prodrug of etoposide at start phase 3 for second line treatment of biliary tract cancer. ... Phase III toll-like receptor 9 agonist for metastatic colorectal cancer. 124.

  • Pharma deals during February 2014 Pharma deals during February 2014

    MK-3475 was awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. ... BATON studies in colorectal cancer and metastatic triple negative breast cancer.

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic ... colorectal cancer and gastrointestinal stromal

  • Pharma deals during September 2012 Pharma deals during September 2012

    advanced KRAS; a wild-type metastatic colorectal cancer (mCRC). ... 665. Symphogen / Merck KGaA. Product licence. Sym004 for advanced KRAS; a wild-type metastatic colorectal cancer (mCRC) (phase I /II).

  • Evidence-based patient pathways for mCRC Evidence-based patient pathways for mCRC

    Evidence-based patient pathways for mCRC. Saving Lives: the metastatic colorectal cancer best practice pathway. ... Challenge. People in the UK are dying prematurely from metastatic colorectal cancer (mCRC) in what appears to be a “ postcode lottery”

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • BMS appoints oncology development head BMS appoints oncology development head

    On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).

  • Boston Biomedical appoints commercial head Boston Biomedical appoints commercial head

    Andrews joins Boston Biomedical – a subsidiary of Japanese firm Dainippon Sumitomo Pharma – to bulk up its commercialisation efforts as lead drug candidate BBI608 nears phase III completion for use in metastatic ... colorectal cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • 90TEN nominated for five Communiqué Awards

    Meanwhile two of the agency’ s campaigns for Sirtex - in collaboration with Denovo Strategy - in metastatic colorectal liver cancer are shortlisted, for Excellence in Media Relations and Excellence in Integrated

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics